Regen BioPharma, Inc. (RGBP)
USD 0.05
(-12.78%)
USD 0.05
(-12.78%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 1.02 Million USD | -81.36% |
| 2022 | 5.48 Million USD | 176.97% |
| 2021 | -7.13 Million USD | -498.75% |
| 2020 | 1.78 Million USD | 141.36% |
| 2019 | -4.32 Million USD | 8.29% |
| 2018 | -4.71 Million USD | 19.25% |
| 2017 | -5.83 Million USD | 24.66% |
| 2016 | -7.75 Million USD | 30.77% |
| 2015 | -11.19 Million USD | -1380.15% |
| 2014 | -756.35 Thousand USD | -113.04% |
| 2013 | -355.03 Thousand USD | 11.52% |
| 2012 | -401.25 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -349.76 Thousand USD | -24.81% |
| 2024 Q2 | -122.47 Thousand USD | 64.98% |
| 2024 Q3 | -117.1 Thousand USD | 4.38% |
| 2023 Q3 | 60.93 Million USD | 320322.47% |
| 2023 Q1 | 3.56 Million USD | -42.51% |
| 2023 Q2 | -19.02 Thousand USD | -100.53% |
| 2023 FY | 1.02 Million USD | -81.36% |
| 2023 Q4 | -280.24 Thousand USD | -100.46% |
| 2022 Q3 | 60.93 Million USD | 145.46% |
| 2022 Q4 | 6.2 Million USD | -89.82% |
| 2022 FY | 5.48 Million USD | 176.97% |
| 2022 Q1 | 2.39 Million USD | 173.34% |
| 2022 Q2 | -134.02 Million USD | -5705.13% |
| 2021 Q3 | -5.61 Million USD | -1569.28% |
| 2021 Q2 | 382.04 Thousand USD | -72.42% |
| 2021 FY | -7.13 Million USD | -498.75% |
| 2021 Q1 | 1.38 Million USD | 43.97% |
| 2021 Q4 | -3.26 Million USD | 41.92% |
| 2020 Q4 | 962.28 Thousand USD | -62.48% |
| 2020 FY | 1.78 Million USD | 141.36% |
| 2020 Q3 | 2.56 Million USD | 162.91% |
| 2020 Q2 | -4.07 Million USD | -268.91% |
| 2020 Q1 | 2.41 Million USD | 29.03% |
| 2019 Q3 | -4.4 Million USD | -1217.41% |
| 2019 Q4 | 1.87 Million USD | 142.42% |
| 2019 FY | -4.32 Million USD | 8.29% |
| 2019 Q1 | 145.24 Thousand USD | 114.91% |
| 2019 Q2 | -334.73 Thousand USD | -330.46% |
| 2018 Q3 | -114.47 Thousand USD | 89.88% |
| 2018 Q4 | -973.97 Thousand USD | -750.8% |
| 2018 FY | -4.71 Million USD | 19.25% |
| 2018 Q1 | -2.78 Million USD | -122.45% |
| 2018 Q2 | -1.13 Million USD | 59.37% |
| 2017 Q3 | -2.62 Million USD | -88.59% |
| 2017 Q4 | -1.25 Million USD | 52.25% |
| 2017 FY | -5.83 Million USD | 24.66% |
| 2017 Q1 | -2.52 Million USD | -3.23% |
| 2017 Q2 | -1.39 Million USD | 44.93% |
| 2016 Q1 | -1.85 Million USD | -209.23% |
| 2016 Q2 | -1.09 Million USD | 41.3% |
| 2016 Q3 | -2.35 Million USD | -116.17% |
| 2016 FY | -7.75 Million USD | 30.77% |
| 2016 Q4 | -2.44 Million USD | -3.76% |
| 2015 Q2 | -8.81 Million USD | -3920.65% |
| 2015 FY | -11.19 Million USD | -1380.15% |
| 2015 Q1 | -219.19 Thousand USD | -12.64% |
| 2015 Q4 | -600.68 Thousand USD | 61.55% |
| 2015 Q3 | -1.56 Million USD | 82.27% |
| 2014 FY | -756.35 Thousand USD | -113.04% |
| 2014 Q1 | -209.52 Thousand USD | -77.78% |
| 2014 Q3 | -166.02 Thousand USD | 10.84% |
| 2014 Q4 | -194.6 Thousand USD | -17.22% |
| 2014 Q2 | -186.2 Thousand USD | 11.13% |
| 2013 Q1 | -91.83 Thousand USD | 0.0% |
| 2013 Q4 | -117.86 Thousand USD | -57.51% |
| 2013 Q2 | -70.5 Thousand USD | 23.23% |
| 2013 Q3 | -74.82 Thousand USD | -6.13% |
| 2013 FY | -355.03 Thousand USD | 11.52% |
| 2012 FY | -401.25 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | 176.643% |
| Arch Therapeutics, Inc. | -6.98 Million USD | 114.657% |
| Evofem Biosciences, Inc. | 52.97 Million USD | 98.068% |
| Nascent Biotech, Inc. | -2.08 Million USD | 149.026% |
| Rebus Holdings, Inc. | -1.02 Million USD | 200.344% |
| Santhera Pharmaceuticals Holding AG | 65.13 Million USD | 98.429% |
| Qrons Inc. | -789.34 Thousand USD | 229.665% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | -632.4 Thousand USD | 261.843% |
| Northwest Biotherapeutics, Inc. | -62.59 Million USD | 101.635% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | 346.344% |
| Skye Bioscience, Inc. | -37.64 Million USD | 102.719% |
| Eiger BioPharmaceuticals, Inc. | -74.96 Million USD | 101.365% |
| Nanobac Pharmaceuticals, Incorporated | -6.57 Million USD | 115.564% |
| Institute of Biomedical Research Corp. | -273.4 Thousand USD | 474.36% |
| SQZ Biotechnologies Company | -79.46 Million USD | 101.288% |
| Intellipharmaceutics International Inc. | -2.89 Million USD | 135.386% |
| Propanc Biopharma, Inc. | -1.82 Million USD | 156.22% |
| Mesoblast Limited | -87.95 Million USD | 101.164% |
| Marizyme, Inc. | -65.34 Million USD | 101.566% |
| Genus plc | 7.9 Million USD | 87.044% |
| VioQuest Pharmaceuticals, Inc. | -10.89 Million USD | 109.397% |
| Pharming Group N.V. | -10.54 Million USD | 109.703% |
| Therapeutic Solutions International, Inc. | -2.16 Million USD | 147.17% |
| CNBX Pharmaceuticals Inc. | -3.71 Million USD | 127.586% |
| Nymox Pharmaceutical Corporation | -8.84 Million USD | 111.573% |
| ContraFect Corporation | -65.15 Million USD | 101.571% |
| PsyBio Therapeutics Corp. | -4.88 Million USD | 120.947% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.72 Million USD | 159.249% |
| IMV Inc. | -36.48 Million USD | 102.805% |
| AXIM Biotechnologies, Inc. | -8.05 Million USD | 112.699% |
| MultiCell Technologies, Inc. | -380.07 USD | 269394.604% |
| ONE Bio Corp. | 8.67 Million USD | 88.204% |
| Accustem Sciences Inc. | -3.74 Million USD | 127.32% |
| RVL Pharmaceuticals plc | -51.69 Million USD | 101.98% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | -1.26 Million USD | 180.773% |
| Q BioMed Inc. | -2.05 Million USD | 149.876% |
| Emmaus Life Sciences, Inc. | -3.73 Million USD | 127.418% |
| Mosaic ImmunoEngineering Inc. | -2.38 Million USD | 142.989% |
| Biomind Labs Inc. | -1.21 Million USD | 184.287% |
| American Oriental Bioengineering, Inc. | -59.72 Million USD | 101.714% |
| Provectus Biopharmaceuticals, Inc. | -3.1 Million USD | 132.998% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | -7.9 Million USD | 112.951% |
| GlobeStar Therapeutics Corporation | -1.94 Million USD | 152.508% |
| THC Farmaceuticals, Inc. | -14.97 Thousand USD | 6934.322% |
| Acro Biomedical Co., Ltd. | -15.87 Million USD | 106.449% |
| Curative Biotechnology, Inc. | -5.81 Million USD | 117.594% |
| GB Sciences, Inc. | -1.36 Million USD | 175.165% |
| Alpha Cognition Inc. | -13.77 Million USD | 107.431% |
| HST Global, Inc. | -146.21 Thousand USD | 800.026% |
| CSL Limited | 2.64 Billion USD | 99.961% |
| Wesana Health Holdings Inc. | -1.75 Million USD | 158.327% |
| Halberd Corporation | -79.67 Thousand USD | 1384.588% |
| Enzolytics Inc. | -2.17 Million USD | 147.018% |
| Agentix Corp. | -1.37 Million USD | 174.48% |
| Resverlogix Corp. | -3.61 Million USD | 128.352% |
| Nuo Therapeutics, Inc. | -3.17 Million USD | 132.273% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -295.05 Million USD | 100.347% |
| Enzon Pharmaceuticals, Inc. | 98 Thousand USD | -944.396% |
| Endonovo Therapeutics, Inc. | 6.92 Million USD | 85.219% |
| RespireRx Pharmaceuticals Inc. | -3.97 Million USD | 125.762% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -3.02 Million USD | 133.822% |
| AVAX Technologies, Inc. | -6.41 Million USD | 115.958% |
| Zenith Capital Corp. | -10.59 Million USD | 109.659% |
| Genscript Biotech Corporation | -95.47 Million USD | 101.072% |
| Ember Therapeutics, Inc. | -23.24 Thousand USD | 4503.7% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | -4.14 Million USD | 124.687% |
| WPD Pharmaceuticals Inc. | -60.44 Thousand USD | 1793.411% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | 151.045% |
| Kadimastem Ltd | -3.3 Million USD | 130.946% |
| Helix BioMedix, Inc. | -1.05 Million USD | 196.918% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | -3.81 Million USD | 126.8% |
| BioStem Technologies, Inc. | -8.48 Million USD | 112.065% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | -441.36 Thousand USD | 331.894% |
| LadRx Corporation | 400.44 Thousand USD | -155.594% |
| Cell Source, Inc. | -5.32 Million USD | 119.234% |
| Regen BioPharma, Inc. | 1.02 Million USD | 0.0% |
| NovAccess Global Inc. | -4.76 Million USD | 121.461% |
| Affymax, Inc. | -14.42 Million USD | 107.096% |
| Itoco Inc. | -1.86 Million USD | 154.762% |
| Rasna Therapeutics, Inc. | -4.44 Million USD | 123.039% |
| Pathfinder Cell Therapy, Inc. | -1.66 Million USD | 161.325% |
| Mobile Lads Corp. | -2.26 Million USD | 145.222% |
| CytoDyn Inc. | -49.84 Million USD | 102.054% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -79.03 Thousand USD | 1395.039% |
| NanoSphere Health Sciences Inc. | -228.12 Thousand USD | 548.657% |
| Alseres Pharmaceuticals, Inc. | -941.52 Thousand USD | 208.707% |
| SYBLEU INC | -180.3 Thousand USD | 667.657% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.61 Million USD | 163.464% |
| International Stem Cell Corporation | -131 Thousand USD | 881.304% |
| Bioxytran, Inc. | -4.28 Million USD | 123.914% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | -54.27 Thousand USD | 1985.886% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | -2.53 Million USD | 140.451% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | -48.07 Million USD | 102.129% |
| Adhera Therapeutics, Inc. | -2.11 Million USD | 148.416% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | -780.88 Thousand USD | 231.07% |
| Innovation Pharmaceuticals Inc. | -3.16 Million USD | 132.308% |
| Neutra Corp. | -233.46 Thousand USD | 538.399% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 105.044% |
| PureTech Health plc | -65.69 Million USD | 101.558% |
| Coeptis Therapeutics, Inc. | -21.26 Million USD | 104.813% |
| IXICO plc | -1.17 Million USD | 186.885% |
| IntelGenx Technologies Corp. | -9.92 Million USD | 110.31% |
| Gelesis Holdings, Inc. | -57.12 Million USD | 101.792% |
| CSL Limited | 2.64 Billion USD | 99.961% |
| Cellectis S.A. | -103.17 Million USD | 100.992% |